Loading
No description yet: the sentence for this tag has not been written. 1 record carries it: 1 key paper.
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
FUTURE-SUPER: first-line subtyping-based treatment in advanced TNBC Fan L, Wang ZH, Ma LX, Wu SY, Wu J, Yu KD, Sui XY, Xu Y, Liu XY, Chen L, Zhang WJ, Jin X, Xiao Q, Shui RH, Xiao Y, Wang H, Yang YS, Huang XY, Cao AY, Li JJ, Di GH, Liu GY, Yang WT, Hu X, Xia Y, Liang QN, Jiang YZ, Shao ZM. · The Lancet. Oncology 2024 This randomised phase 2 trial found longer progression-free survival with a specified subtype-based combination strategy than with nab-paclitaxel alone, with more serious treatment-related adverse events. | Triple-negative breast cancer | education-audit |